1. Lever WF: Pemphigus and Pemphigoid. Springfield, IL, Charles C. Thomas, 1965
2. Beutner EH, Jordon RE: Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 117:505, 1964
3. Krain LS: Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955–1973. Arch Dermatol 110:862, 1974
4. Pisanti S et al: Pemphigus vulgaris: Incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 38:382, 1974
5. Hietanen J, Salo OP: Pemphigus: An epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol (Stockh) 62:491, 1982
6. Bastuji-Garin S et al: Comparative epidemiology of pemphigus in Tunisia and France: Unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 104:302, 1995
7. Chams-Davatchi C et al: Pemphigus: Analysis of 1209 cases. Int J Dermatol 44:470, 2005
8. Goon AT, Tan SH: Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore. Australas J Dermatol 42:172, 2001
9. Langan SM et al: Bullous pemphigoid and pemphigus vulgaris–Incidence and mortality in the UK: Population based cohort study. BMJ 337:a180, 2008
10. Marazza G et al: Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br J Dermatol 161:861, 2009
11. Diaz LA et al: Endemic pemphigus foliaceus (fogo selvagem): II. Current and historical epidemiological aspects. J Invest Dermatol 92:4, 1989
12. Aoki V et al: Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 9:34, 2004
13. Lombardi C et al: Environmental risk factors in endemic pemphigus foliaceus (Fogo selvagem). J Invest Dermatol 98:847, 1992
14. Warren SJ et al: The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. New Engl J Med 343:23, 2000
15. Diaz LA et al: Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. J Invest Dermatol 123:1045, 2004
16. Uzun S et al: Pemphigus in the Mediterranean region of Turkey: A study of 148 cases. Int J Dermatol 45:523, 2006
17. V'lckova-Laskoska MT et al: Epidemiology of pemphigus in Macedonia: A 15-year retrospective study (1990–2004). Int J Dermatol 46:253, 2007
18. Salmanpour R et al: Epidemiology of pemphigus in south-western Iran: A 10-year retrospective study (1991–2000). Int J Dermatol 45:103, 2006
19. Michailidou EZ et al: Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients. Int J Dermatol 46:356, 2007
20. Ljubojevic S et al: Pemphigus vulgaris: A review of treatment over a 19-year period. J Eur Acad Dermatol Venereol 16:599, 2002
21. Abreu-Velez AM et al: A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 49:599, 2003
22. Tallab T et al: The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol 40:570, 2001
23. Simon DG et al: Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol 116:1035, 1980
24. Tsankov N et al: Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980–1995). Int J Dermatol 39:104, 2000
25. Micali G, Musumeci ML, Nasca MR: Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int J Dermatol 37:197, 1998
26. Metry DW, Hebert AA, Jordon RE: Nonendemic pemphigus foliaceus in children. J Am Acad Dermatol 46:419, 2002
27. Koulu L et al: Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J Exp Med 160:1509, 1984
28. Stanley JR et al: A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J Immunol 136:1227, 1986
29. Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869, 1991
30. Payne AS et al: Desmosomes and disease: Pemphigus and bullous impetigo. Curr Opin Cell Biol 16:536, 2004
31. Stanley JR, Amagai M: Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 355:1800, 2006
32. Amagai M et al: The extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol 102:402, 1994
33. Chitaev NA, Troyanovsky SM: Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J Cell Biol 138:193, 1997
34. Stanley JR, Klaus Kovtun V, Sampaio SA: Antigenic specificity of fogo selvagem autoantibodies is similar to North American pemphigus foliaceus and distinct from pemphigus vulgaris autoantibodies. J Invest Dermatol 87:197, 1986
35. Ishii K et al: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159:2010, 1997
36. Eyre RW, Stanley JR: Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest 81:807, 1988
37. Ding X et al: Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 109:592, 1997
38. Amagai M et al: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 40:170, 1999
39. Miyagawa S et al: Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: Correlation with disease progression. Br J Dermatol 141:1084, 1999
40. Schiltz JR, Michel B: Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 67:254, 1976
41. Anhalt GJ et al: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189, 1982
42. Rock B, Labib RS, Diaz LA: Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 85:296, 1990
43. Amagai M et al: Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 90:919, 1992
44. Amagai M et al: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 94:59, 1994
45. Ding X et al: The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 112:739, 1999
46. Amagai M et al: Antigen-specific immunoabsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104:895, 1995
47. Chowdhury MMU, Natarajan S: Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Br J Dermatol 139:500, 1998
48. Kljuic A et al: Desmoglein 4 in hair follicle differentiation and epidermal adhesion: Evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 113:249, 2003
49. Nagasaka T et al: Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 114:1484, 2004
50. Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris antibody identifies pemphaxin. J Biol Chem 275:29466, 2000
51. Evangelista F, Dasher DA, Diaz LA, et al: E-cadherin is an additional immunological target for pemphigus autoantibodies. J Invest Dermatol 128:1710, 2008
52. Wilgram GF, Caulfield JB, Madgic EB: An electron microscopic study of acantholysis and dyskeratosis in pemphigus foliaceus. J Invest Dermatol 43:287, 1964
53. Guedes
AC et al: Ultrastructural aspects of mucosas in endemic pemphigus foliaceus.
Arch Dermatol 138:949, 2002
54. Hashimoto K, Lever WF: An electron microscopic study on pemphigus vulgaris of the mouth and the skin with special reference to the intercellular cement. J Invest Dermatol 48:540, 1967
55. Diercks GF, Pas HH, Jonkman MF: The ultrastructure of acantholysis in pemphigus vulgaris. Br J Dermatol 160:460, 2009
56. Shimizu A et al: Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris. Arch Dermatol Res 294:318, 2002
57. Shimizu A et al: IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. J Invest Dermatol 122(5):1145-1153, 2004
58. Bystryn JC, Grando SA: A novel explanation for acantholysis in pemphigus vulgaris: The basal cell shrinkage hypothesis. J Am Acad Dermatol 54:513, 2006
59. Wang W, Amagai M, Ishiko A: Desmosome splitting is a primary ultrastructural change in the acantholysis of pemphigus. J Dermatol Sci 54:59, 2009
60. Anhalt GJ et al: Defining the role of complement in experimental pemphigus vulgaris in mice. J Immunol 137:2835, 1986
61. Payne AS et al: Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 115:888, 2005
62. Ishii K et al: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol 128:939, 2008
63. Futei Y et al: Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. J Invest Dermatol 115:829, 2000
64. Li N et al: The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 197:1501, 2003
65. Hacker-Foegen MK et al: Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. J Invest Dermatol 121:1373, 2003
66. Sekiguchi M et al: Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 167:5439, 2001
67. Boggon TJ et al: C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 296:1308, 2002
68. Al-Amoudi A et al: The molecular architecture of cadherins in native epidermal desmosomes. Nature 450:832, 2007
69. Aoyama Y, Kitajima Y: Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 112:67, 1999
70. Sato M, Aoyama Y, Kitajima Y: Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab Invest 80:1583, 2000
71. Calkins CC et al: Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 281:7623, 2006
72. Mao X, Choi EJ, Payne AS: Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies. J Invest Dermatol 129:908, 2009
73. Koch PJ et al: Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 137:1091, 1997
74. Amagai M et al: Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 6:1275, 2000
75. Rivitti EA et al: Pemphigus foliaceus autoantibodies bind both epidermis and squamous mucosal epithelium, but tissue injury is detected only in the epidermis. The Cooperative Group on Fogo Selvagem Research. J Am Acad Dermatol 31:954, 1994
76. Mahoney MG et al: Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 103:461, 1999
77. Wu H et al: Protection of neonates against pemphigus foliaceus by desmoglein 3. N Engl J Med 343:31, 2000
78. Hanakawa Y, Matsuyoshi N, Stanley JR: Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in keratinocyte adhesion. J Invest Dermatol 119:27, 2002
79. Rocha-Alvarez R et al: Pregnant women with endemic pemphigus foliaceus (Fogo Selvagem) give birth to disease-free babies. J Invest Dermatol 99:78, 1992
80. Berkowitz P et al: p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci U S A 103:12855, 2006
81. Waschke J et al: Inhibition of Rho A activity causes pemphigus skin blistering. J Cell Biol 175:721, 2006
82. Sharma P, Mao X, Payne AS: Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci 48:1, 2007
83. Wucherpfennig KW, Strominger JL: Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: A mechanism for MHC- linked susceptibility to human autoimmune diseases [comment]. J Exp Med 181:1597, 1995
84. Pavoni DP et al: Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes. Genes Immun 4:110, 2003
85. Hertl M, Eming R, Veldman C: T cell control in autoimmune bullous skin disorders. J Clin Invest 116:1159, 2006
86. Wucherpfennig KW et al: Structural basis for major histocompatibility complex (MHC)- linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self- peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A 92:11935, 1995
87. Lin MS et al: Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 99:31, 1997
88. Hertl M et al: Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol 110:388, 1998
89. Hertl M et al: Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 110:62, 1998
90. Veldman CM et al: T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol 172:3883, 2004
91. Veldman C et al: Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol 172:6468, 2004
92. Yamagami J et al: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus. J Immunol 183:5615, 2009
93. Hacker-Foegen MK, Fairley JA, Lin MS: T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris. J Invest Dermatol 121:1365, 2003
94. Muramatsu T et al: Pemphigus vulgaris exacerbated by exposure to sunlight. J Dermatol 23:559, 1996
95. Reis VM et al: UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol 42:571, 2000
96. Grando SA et al: History and clinical significance of mechanical symptoms in blistering dermatoses: A reappraisal. J Am Acad Dermatol 48:86, 2003
97. Nelson CG et al: Pemphigus vegetans of Hallopeau: Immunofluorescent studies. Arch Dermatol 113:942, 1977
98. Ahmed AR, Blose DA: Pemphigus vegetans. Neumann type and Hallopeau type. Int J Dermatol 23:135, 1984
99. Yoshida K et al: Cutaneous type pemphigus vulgaris: A rare clinical phenotype of pemphigus. J Am Acad Dermatol 52:839, 2005
100. Trattner A et al: Esophageal involvement in pemphigus vulgaris: A clinical, histologic, and immunopathologic study. J Am Acad Dermatol 24:223, 1991
101. Rao PN et al: Study of upper gastrointestinal tract involvement in pemphigus by esophago-gastro-duodenoscopy. Indian J Dermatol Venereol Leprol 72:421, 2006
102. Malik M, Ahmed AR: Involvement of the female genital tract in pemphigus vulgaris. Obstet Gynecol 106:1005, 2005
103. Hale EK, Bystryn JC: Laryngeal and nasal involvement in pemphigus vulgaris. J Am Acad Dermatol 44:609, 2001
104. Espana A et al: Ear, nose and throat manifestations in pemphigus vulgaris. Br J Dermatol 156:733, 2007
105. Hodak E et al: Conjunctival involvement in pemphigus vulgaris: A clinical, histopathological and immunofluorescence study. Br J Dermatol 123:615, 1990
106. Daoud YJ et al: Ocular pemphigus. J Am Acad Dermatol 53:585, 2005
107. Akhyani M et al: Cervicovaginal involvement in pemphigus vulgaris: A clinical study of 77 cases. Br J Dermatol 158:478, 2008
108. Onuma K et al: Pemphigus vulgaris of the vagina–Its cytomorphologic features on liquid-based cytology and pitfalls: Case report and cytological differential diagnosis. Diagn Cytopathol 37:832, 2009
109. Suami M et al: Keratolysis in a patient with pemphigus vulgaris. Br J Ophthalmol 85:1263, 2001
110. Igawa K, Matsunaga T, Nishioka K: Involvement of UV-irradiation in pemphigus foliaceus. J Eur Acad Dermatol Venereol 18:216, 2004
111. Kano Y et al: Pemphigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions. Dermatology 201:132, 2000
112. Senear FE, Usher B: An unusual type of pemphigus combining features of lupus erythematosus. Arch Dermatol Syphilol 13:761, 1926
113. Senear FE, Kingery LB: Pemphigus erythematosus. Arch Dermatol Syphilol 60:238, 1949
114. Jablonska S et al: Pathogenesis of pemphigus erythematosus. Arch Dermatol Res 258:135, 1977
115. Amerian ML, Ahmed AR: Pemphigus erythematosus. Senear-Usher syndrome. Int J Dermatol 24:16, 1985
116. Fainaru O et al: Pemphigus vulgaris in pregnancy: A case report and review of literature. Hum Reprod 15:1195, 2000
117. Eyre RW, Stanley JR: Maternal pemphigus foliaceus with cell surface antibody bound in neonatal epidermis. Arch Dermatol 124:25, 1988
118. Avalos-Diaz E et al: Transplacental passage of maternal pemphigus foliaceus autoantibodies induces neonatal pemphigus. J Am Acad Dermatol 43:1130, 2000
119. Hirsch R et al: Neonatal pemphigus foliaceus. J Am Acad Dermatol 49:S187, 2003
120. Kanwar AJ, Dhar S, Kaur S: Further experience with pemphigus in children. Pediatr Dermatol 11:107, 1996
121. Mutasim DF, Pelc NJ, Anhalt GJ: Drug-induced pemphigus. Dermatol Clin 11:463, 1993
122. Korman NJ et al: Drug-induced pemphigus: Autoantibodies directed against the pemphigus antigen complexes are present in
penicillamine and captopril-induced pemphigus.
J Invest Dermatol 96:273, 1991
123. Ruocco V, Brenner S, Lombardi ML: A case of diet-related pemphigus. Dermatology 192:373, 1996
124. Tur E, Brenner S: Diet and pemphigus. In pursuit of exogenous factors in pemphigus and fogo selvagem. Arch Dermatol 134:1406, 1998
125. Mehta JN, Martin AG: A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol 136:15, 2000
126. Nguyen VT et al: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 140:327, 2004
127. Iraji F, Yoosefi A: Healing effect of
pilocarpine gel 4% on skin lesions of pemphigus vulgaris.
Int J Dermatol 45:743, 2006
128. Chernyavsky AI et al: Differential coupling of M1 muscarinic and alpha 7 nicotinic receptors to inhibition of pemphigus acantholysis. J Biol Chem 283:3401, 2008
129. Pullan RD et al: Transdermal
nicotine for active ulcerative colitis.
New Engl J Med 330:811, 1994
130. Patten SF, Dijkstra JW: Associations of pemphigus and autoimmune disease with malignancy or thymoma. Int J Dermatol 33:836, 1994
131. Udey MC, Stanley JR: Pemphigus: Diseases of anti-desmosomal autoimmunity. JAMA 282:572, 1999
132. Emmerson RW, Wilson-Jones E: Eosinophilic spongiosis in pemphigus. Arch Dermatol 97:252, 1968
133. Beutner EH et al: Autoantibodies in pemphigus vulgaris. JAMA 192:682, 1965
134. Judd KP, Lever WF: Correlation of antibodies in skin and serum with disease severity in pemphigus. Arch Dermatol 115:428, 1979
135. Chorzelski T, Jablonska S, Blaszczyk M: Immunopathological investigations in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 80:211, 1968
136. Harman KE et al: The use of two substrates to improve the senstivity of indirect immunofluorscence in the diagnosis of pemphigus. Br J Dermatol 142:1135, 2000
137. Krasny SA, Beutner EH, Chorzelski TP: Specificity and sensitivity of indirect and direct immunofluorescent findings in the diagnosis of pemphigus. In: Immunopathology of the Skin, edited by EH Beutner, TP Chorzelski, V Kumar. New York City, NY, John Wiley and Sons, 1987, pp. 207-247
138. O'Loughlin S, Goldman GC, Provost TT: Fate of pemphigus antibody following successful therapy. Preliminary evaluation of pemphigus antibody determinations to regulate therapy. Arch Dermatol 114:1769, 1978
139. Aberer W et al:
Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up.
J Am Acad Dermatol 16:527, 1987
140. Amagai M et al: Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140:351, 1999
141. Amagai M et al: Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent. J Invest Dermatol 105:243, 1995
142. Cheng SW et al: Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 147:261, 2002
143. Ishii K et al: Development of pemphigus vulgaris in a patient with pemphigus foliaceus: Antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 42:859, 2000
144. Komai A et al: The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol 144:1177, 2001
145. Tsuji Y et al: Clinical and serological transition from pemphigus vulgaris to pemphigus foliaceus demonstrated by desmoglein ELISA system. Arch Dermatol 138:95, 2002
146. Arteaga LA et al: A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. J Invest Dermatol 118:806, 2002
147. Carson PJ, Hameed A, Ahmed AR: Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 34:645, 1996
148. Bystryn JC, Rudolph JL: Pemphigus. Lancet 366:61, 2005
149. Stanley JR: Therapy of pemphigus vulgaris. Arch Dermatol 135:76, 1999
150. Bystryn JC, Steinman NM: The adjuvant therapy of pemphigus. An update. Arch Dermatol 132:203, 1996
151. Risser J, Lewis K, Weinstock MA: Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 145:1005, 2009
152. Ahmed AR, Moy R: Death in pemphigus. J Am Acad Dermatol 7:221, 1982
153. Herbst A, Bystryn JC: Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 42:422, 2000
154. Mimouni D et al: Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 49:1059, 2003
155. Seidenbaum M, David M, Sandbank M: The course and prognosis of pemphigus. A review of 115 patients. Int J Dermatol 27:580, 1988
156. Murrell DF et al: Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043, 2008
157. Pfütze M et al: Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 17:4, 2007
158. Rosenbach M et al: Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 129:2404, 2008
159. Rosenberg FR, Sanders S, Nelson CT: Pemphigus: A 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 112:962, 1976
160. Hirone T: Pemphigus: A survey of 85 patients between 1970 and 1974. J Dermatol 5:43, 1978
161. Ratnam KV, Phay KL, Tan CK: Pemphigus therapy with oral
prednisolone regimens. A 5-year study.
Int J Dermatol 29:363, 1990
162. Fine JD: Management of acquired bullous skin diseases. N Engl J Med 333:1475, 1995
163. Harman KE, Albert S, Black MM: Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149:926, 2003
164. Nguyen VT et al: Pemphigus vulgaris IgG and
methylprednisolone exhibit reciprocal effects on keratinocytes.
J Biol Chem 279:2135, 2004
166. Chams-Davatchi C et al: Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 57:622, 2007
168. Weinshilboum RM, Sladek SL:
Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity.
Am J Hum Genet 32:651, 1980
169. Schaeffeler E et al: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14:407, 2004
170. Reuther LO et al: Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol 59:797, 2004
171. Enk AH, Knop J:
Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris.
Arch Dermatol 135:54, 1999
172. Mimouni D et al: Treatment of pemphigus vulgaris and pemphigus foliaceus with
mycophenolate mofetil.
Arch Dermatol 139:739, 2003
173. Roche Pharmaceuticals: Cellcept prescribing information. 2007
175. Cummins DL et al: Oral
cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.
J Am Acad Dermatol 49:276, 2003
176. Pasricha JS, Das SS: Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol 31:875, 1992
177. Kanwar AJ, Kaur S, Thami GP: Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology 204:228, 2002
178. Hayag MV, Cohen JA, Kerdel FA: Immunoablative high-dose
cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris.
J Am Acad Dermatol 43:1065, 2000
179. Nousari CH, Brodsky R, Anhalt GJ: Evaluating the role of immunoablative high-dose
cyclophosphamide therapy in pemphigus vulgaris.
J Am Acad Dermatol 49:148, 2003
180. Heaphy MR, Albrecht J, Werth VP:
Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
Arch Dermatol 141:699, 2005
181. Werth VP et al: Multicenter randomized, double-blind, placebo-controlled, clinical trial of
dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
Arch Dermatol 144:25, 2008
182. Eming R et al:
Rituximab exerts a dual effect in pemphigus vulgaris.
J Invest Dermatol 128:2850, 2008
183. Joly P et al: A single cycle of
rituximab for the treatment of severe pemphigus.
New Engl J Med 357:545, 2007
184. Hertl M, Eming R, Borradori L:
Rituximab (anti-CD20 monoclonal antibody)–Ultimate or first choice in pemphigus?
Dermatology 214:275, 2007
185. Allen KJ, Wolverton SE: The efficacy and safety of
rituximab in refractory pemphigus: A review of case reports.
J Drugs Dermatol 6:883, 2007
186. Cianchini G et al: Treatment of severe pemphigus with
rituximab: Report of 12 cases and a review of the literature.
Arch Dermatol 143:1033, 2007
187. Kolstad A et al: Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139, 2007
188. Teichmann LL et al: Fatal
Pneumocystis pneumonia following
rituximab administration for rheumatoid arthritis.
Rheumatology 47:1256, 2008
189. Yu Z, Lennon
VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.
New Engl J Med 340:227, 1999
190. Li N et al: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440, 2005
191. Czernik A, Beutner EH, Bystryn JC: Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 58:796, 2008
192. Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 43:1049, 2000
193. Ahmed AR, Dahl MV: Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 139:1051, 2003
194. Amagai M et al: A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60:595, 2009
195. Katz KA et al: Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 139:991, 2003
196. Ahmed AR et al: Treatment of pemphigus vulgaris with
rituximab and intravenous immune globulin.
N Engl J Med 355:1772, 2006
197. Guillaume JC et al: Controlled study of plasma exchange in pemphigus. Arch Dermatol 124:1659, 1988
198. Turner MS, Sutton D, Sauder DN: The use of plasmapheresis and immuosupression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 43:1058, 2000
199. Euler HH, Loffler H, Christophers E: Synchronization of plasmapheresis and pulse
cyclophosphamide therapy in pemphigus vulgaris.
Arch Dermatol 123:1205, 1987
200. Shimanovich I et al: Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768, 2006
201. Werth VP: Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 132:1435, 1996
202. Roujeau JC: Pulse glucocorticoid therapy. The ‘big shot’ revisited. Arch Dermatol 132:1499, 1996
203. Mentink LF et al: Randomized controlled trial of adjuvant oral
dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial.
Arch Dermatol 142:570, 2006